2024年5月29日 · Wyost is a monoclonal antibody that targets and inhibits RANK ligand (RANKL) and belongs to the class of medicines known as RANK ligand (RANKL) inhibitors. Wyost is an interchangeable biosimilar to Xgeva (denosumab) that was FDA-approved on 5 March 2024.

Wyost is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. Wyost is intended for subcutaneous route only and should not be...

2024年5月31日 · Wyost is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. Wyost is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally.

2024年3月5日 · Wyost® (denosumab-bbdz) is an FDA-approved biosimilar to denosumab, used for treating bone-related conditions such as preventing bone complications in patients with multiple myeloma, treating adults and adolescents with giant cell tumor of bone, and treating hypercalcemia of malignancy that does not respond to standard therapies.

2024年3月22日 · Wyost is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery.

— Wyost is the first FDA-approved biosimilar to Xgeva. The approval of Wyost is based on review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity to its reference product, Xgeva.

Wyost should be administered under the responsibility of a healthcare professional. Supplementation of at least 500 mg calcium and 400 IU vitamin D daily is required in all patients, unless hypercalcaemia is present (see section 4.4). Patients treated with Wyost should be given the package leaflet and the patient reminder card.

Wyost is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery.

The drug WYOST contains one active pharmaceutical ingredient (API): Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of …

2024年3月12日 · Wyost (denosumab-bbdz) is a RANK ligand (RANKL) inhibitor interchangeable biosimilar to Xgeva (denosumab) indicated for the prevention of skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors, treatment of giant cell tumor of bone, and treatment of hypercalcemia of malignancy.